Usual antibiotic treatment — Competitive Intelligence Brief

Usual antibiotic treatment (Usual antibiotic treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic. Area: Infectious disease.

phase 3 Beta-lactam antibiotic Penicillin-binding proteins Infectious disease Small molecule

Target snapshot

Usual antibiotic treatment (Usual antibiotic treatment) — Assistance Publique - Hôpitaux de Paris. This drug inhibits bacterial cell wall synthesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Usual antibiotic treatment TARGET	Usual antibiotic treatment	Assistance Publique - Hôpitaux de Paris	phase 3	Beta-lactam antibiotic	Penicillin-binding proteins
CEPHALEXIN	CEPHALEXIN		marketed	First-generation cephalosporin	Penicillin-binding proteins (PBPs)	1971-01-01
Co-amoxiclav	Co-amoxiclav	Imperial College London	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins (PBPs); bacterial beta-lactamases
Imipenem/Cilastatin/Relebactam	Imipenem/Cilastatin/Relebactam	Evopoint Biosciences Inc.	marketed	Carbapenem antibiotic with beta-lactamase inhibitor	Bacterial penicillin-binding proteins; serine beta-lactamases
amoxicillin/clavulanate potassium 1gm	amoxicillin/clavulanate potassium 1gm	GlaxoSmithKline	marketed	Beta-lactam antibiotic with beta-lactamase inhibitor	Penicillin-binding proteins (PBPs); bacterial beta-lactamase
I.V cefuroxime 750 mg*3/d for 2 days	I.V cefuroxime 750 mg*3/d for 2 days	Western Galilee Hospital-Nahariya	marketed	Second-generation cephalosporin	Penicillin-binding proteins (PBPs)
Meropenem Injection	Meropenem Injection	Institute of Liver and Biliary Sciences, India	marketed	Carbapenem antibiotic	Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic class)

1. Pfizer · 2 drugs in this class
2. Bayer · 1 drug in this class
3. Belén Retamal-Valdes · 1 drug in this class
4. Benova (Tianjin) Innovative medicine Research Co., Ltd. · 1 drug in this class
5. Esraa Salah Mohamed Abdallah Eladl · 1 drug in this class
6. Incheon St.Mary's Hospital · 1 drug in this class
7. International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 1 drug in this class
8. KEMRI-Wellcome Trust Collaborative Research Program · 1 drug in this class
9. National Taiwan University Hospital · 1 drug in this class
10. Pfizer Inc. · 1 drug in this class